FDA today released a letter of enforcement discretion covering three qualified health claims regarding the relationship between magnesium in conventional foods and dietary supplements and reduced risk of high blood pressure. The letter follows a petition from the Center for Magnesium Education and Research. After consideration of the petition and supporting research literature, FDA stated that it would consider applying enforcement discretion for the following claims:
“Inconsistent and inconclusive scientific evidence suggests that diets with adequate magnesium may reduce the risk of high blood pressure (hypertension), a condition associated with many factors.”
“Consuming diets with adequate magnesium may reduce the risk of high blood pressure (hypertension). However, the FDA has concluded that the evidence is inconsistent and inconclusive.”
“Some scientific evidence suggests that diets with adequate magnesium may reduce the risk of high blood pressure (hypertension), a condition associated with many factors. The FDA has concluded that the scientific evidence supporting this claim is inconsistent and not conclusive.”
FDA stated that application of enforcement discretion for these claims will be based on the use of factors described in Section IV of the letter, including product levels of magnesium and other nutrients.
